116 related articles for article (PubMed ID: 21692696)
1. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
Morse MA; Bradley DA; Keler T; Laliberte RJ; Green JA; Davis TA; Inman BA
Expert Rev Vaccines; 2011 Jun; 10(6):733-42. PubMed ID: 21692696
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
He LZ; Weidlick J; Sisson C; Marsh HC; Keler T
Cell Mol Immunol; 2015 Nov; 12(6):719-28. PubMed ID: 25345808
[TBL] [Abstract][Full Text] [Related]
3. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.
Morse MA; Chapman R; Powderly J; Blackwell K; Keler T; Green J; Riggs R; He LZ; Ramakrishna V; Vitale L; Zhao B; Butler SA; Hobeika A; Osada T; Davis T; Clay T; Lyerly HK
Clin Cancer Res; 2011 Jul; 17(14):4844-53. PubMed ID: 21632857
[TBL] [Abstract][Full Text] [Related]
4. The fusion protein of HSP65 with tandem repeats of beta-hCG acting as a potent tumor vaccine in suppressing hepatocarcinoma.
Xiangbing H; Yankai Z; Ming L; Yong L; Yu Z; Huiyong Z; Yingying C; Jing H; Yun X; Liang J; Rongyue C; Jingjing L
Int Immunopharmacol; 2010 Feb; 10(2):230-8. PubMed ID: 19913113
[TBL] [Abstract][Full Text] [Related]
5. Human chorionic gonadotropin as a target for cancer vaccines.
Triozzi PL; Stevens VC
Oncol Rep; 1999; 6(1):7-17. PubMed ID: 9864394
[TBL] [Abstract][Full Text] [Related]
6. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J; Kluger H; Tejwani S; Green J; Ramakrishna V; Crocker A; Vitale L; Yellin M; Davis T; Keler T
Sci Transl Med; 2014 Apr; 6(232):232ra51. PubMed ID: 24739759
[TBL] [Abstract][Full Text] [Related]
7. Ten tandem repeats of beta-hCG 109-118 enhance immunogenicity and anti-tumor effects of beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.
Yankai Z; Rong Y; Yi H; Wentao L; Rongyue C; Ming Y; Taiming L; Jingjing L; Jie W
Biochem Biophys Res Commun; 2006 Jul; 345(4):1365-71. PubMed ID: 16725110
[TBL] [Abstract][Full Text] [Related]
8. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.
Ramakrishna V; Vasilakos JP; Tario JD; Berger MA; Wallace PK; Keler T
J Transl Med; 2007 Jan; 5():5. PubMed ID: 17254349
[TBL] [Abstract][Full Text] [Related]
10. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the immunogenicity of a single chain chimeric peptide composed of hCGβ and oLHα for inhibition of the growth of hCGβ-expressing cancer cells.
Jiang C; Jiang Y; Huang Z; Shen W; Wang J; Shen Q
Cancer Immunol Immunother; 2010 Dec; 59(12):1771-9. PubMed ID: 20809357
[TBL] [Abstract][Full Text] [Related]
12. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
[TBL] [Abstract][Full Text] [Related]
13. [Pilot trial of vaccines based on autologous dendritic cells loaded in vitro with tumor antigens in the treatment of cancer of the urinary bladder].
Shoua AB; Sergienco NF; Sitnikov NV; Chkadua GZ
Urologiia; 2008; (5):54-7. PubMed ID: 19069498
[TBL] [Abstract][Full Text] [Related]
14. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin.
Purswani S; Talwar GP
Vaccine; 2011 Mar; 29(12):2341-8. PubMed ID: 21272600
[TBL] [Abstract][Full Text] [Related]
15. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
17. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta.
He LZ; Ramakrishna V; Connolly JE; Wang XT; Smith PA; Jones CL; Valkova-Valchanova M; Arunakumari A; Treml JF; Goldstein J; Wallace PK; Keler T; Endres MJ
Clin Cancer Res; 2004 Mar; 10(6):1920-7. PubMed ID: 15041707
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based treatment of cancer: closing in on a cellular therapy.
Valone FH; Small E; MacKenzie M; Burch P; Lacy M; Peshwa MV; Laus R
Cancer J; 2001; 7 Suppl 2():S53-61. PubMed ID: 11777265
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]